OMTRYG Drug Patent Profile

« Back to Dashboard

Which patents cover Omtryg, and what generic alternatives are available?

Omtryg is a drug marketed by Osmotica Pharm Us and is included in one NDA.

The generic ingredient in OMTRYG is omega-3-acid ethyl esters type a. There is one drug master file entry for this compound. Additional details are available on the omega-3-acid ethyl esters type a profile page.

Summary for OMTRYG

US Patents:	0
Applicants:	1
NDAs:	1
What excipients (inactive ingredients) are in OMTRYG?	OMTRYG excipients list
DailyMed Link:	OMTRYG at DailyMed

US Patents and Regulatory Information for OMTRYG

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Osmotica Pharm Us	OMTRYG	omega-3-acid ethyl esters type a	CAPSULE;ORAL	204977-001	Apr 23, 2014		DISCN	Yes	No

Omtryg Market Dynamics and Financial Trajectory

Last updated: August 21, 2026

Omtryg was a niche prescription omega-3 product with limited commercial differentiation from Lovaza and generic omega-3-acid ethyl esters. Its U.S. approval created a short-lived branded opportunity, but the product entered a market already exposed to generic substitution, weak pricing power, and competition from Vascepa. Trygg Pharma did not publicly report Omtryg revenue, and no evidence indicates that Omtryg developed into a material standalone pharmaceutical franchise.

What is Omtryg and how was it positioned?

Omtryg is a prescription omega-3-acid ethyl ester product containing eicosapentaenoic acid, or EPA, and docosahexaenoic acid, or DHA. The product was approved by the U.S. Food and Drug Administration for use with diet to reduce triglyceride levels in adults with severe hypertriglyceridemia, generally defined as triglycerides of at least 500 mg/dL.[1]

Attribute	Omtryg
Active ingredient	Omega-3-acid ethyl esters
Principal components	EPA and DHA
Dosage form	1-gram softgel capsules
FDA application	NDA 205977
Approval pathway	505(b)(2) application
U.S. approval	2014
Approved indication	Severe hypertriglyceridemia
Commercial sponsor	Trygg Pharma, Inc.
Key reference product	Lovaza
Cardiovascular-outcome claim	None established in the FDA label

Omtryg was positioned as an alternative prescription omega-3 product rather than as a clinically differentiated cardiovascular therapy. The FDA label states that the effect of Omtryg on cardiovascular mortality and morbidity had not been determined.[1]

The product’s clinical and commercial profile was therefore narrower than that of later products such as Vascepa, which uses purified icosapent ethyl and ultimately obtained a cardiovascular-risk-reduction indication.

When did Omtryg enter the U.S. market?

The FDA approved Omtryg in 2014. Its approval was based on the 505(b)(2) regulatory pathway, which allows an applicant to rely in part on findings for an existing product while providing product-specific data.

The approval created a limited regulatory window rather than a durable monopoly. The product entered an established category containing Lovaza and other omega-3 prescription products. FDA approval did not establish a broad cardiovascular indication, and the product was approved only for triglyceride reduction.

Omtryg regulatory timeline

Date	Event	Commercial relevance
2014	FDA approval of NDA 205977	Established U.S. marketing authorization
2014-2017	Initial post-approval commercial period	Period of potential regulatory exclusivity and branded launch
Subsequent years	Growth of generic omega-3-acid ethyl ester supply	Reduced differentiation and pricing power
Current market position	Limited evidence of active branded commercial presence	Omtryg is not a major U.S. prescription omega-3 brand

The FDA approval label and Drugs@FDA record remain the primary sources for the product’s approved indication, sponsor information, and labeling history.[1]

How large was the Omtryg market?

Omtryg operated in a large but increasingly commoditized prescription omega-3 market. The category had three commercial layers:

1. Branded omega-3-acid ethyl ester products, led historically by Lovaza.
2. Generic omega-3-acid ethyl ester products.
3. Differentiated EPA products, principally Vascepa and generic icosapent ethyl.

Omtryg’s addressable market was constrained by the following factors:

• Severe hypertriglyceridemia represented a narrower population than general cardiovascular-risk management.
• Omega-3-acid ethyl ester products were subject to generic substitution.
• EPA and DHA mixtures were clinically differentiated from purified EPA products.
• Prescription omega-3 products competed with lower-cost dietary supplements, even though supplement quality and regulatory status differed.
• The absence of a cardiovascular-outcome claim limited physician and payer differentiation.

The broader U.S. prescription omega-3 market generated substantial revenue during the peak Lovaza period, but that value did not transfer proportionally to Omtryg. Lovaza had established brand recognition and a large prescriber base before Omtryg launched. Generic entry then compressed the market’s average selling price.

What was Omtryg’s financial trajectory?

Omtryg’s financial trajectory was likely characterized by a short branded launch period followed by market-share pressure and declining economic value. Trygg Pharma was a private company and did not publish segment-level Omtryg sales comparable to the disclosures available from large public pharmaceutical companies.

Financial factor	Effect on Omtryg
No publicly disclosed standalone revenue	Prevents verification of product-level sales
Established Lovaza market	Increased prescriber and payer competition
Generic omega-3 entry	Reduced net pricing
Narrow triglyceride indication	Limited volume expansion
No cardiovascular indication	Restricted premium positioning
Private-company ownership	Limited visibility into margins, spending, and cash flow
Low formulation complexity	Reduced barriers to competing products

Omtryg’s economics depended on securing formulary placement, maintaining prescriptions before generic substitution, and achieving sufficient volume to offset manufacturing, distribution, and promotional costs. Those conditions were unfavorable for a late entrant into a product class with established generic competition.

The product did not develop the commercial profile of a platform asset. There is no widely reported evidence of large-scale licensing revenue, major acquisition value attributable to Omtryg, or material contribution to the financial results of a public pharmaceutical company.

How did Omtryg compare with Lovaza and Vascepa?

Omtryg was commercially weaker than both major comparator products for different reasons.

Product	Active ingredient	Main indication	Commercial differentiation	Market risk
Omtryg	EPA and DHA ethyl esters	Severe hypertriglyceridemia	Limited formulation and brand differentiation	High generic substitution risk
Lovaza	EPA and DHA ethyl esters	Severe hypertriglyceridemia	First-mover brand and established commercial base	High generic erosion
Vascepa	Icosapent ethyl, purified EPA	Hypertriglyceridemia; later cardiovascular-risk reduction	Purified EPA and outcome-based positioning	Generic and patent litigation exposure
Generic omega-3-acid ethyl esters	EPA and DHA ethyl esters	Severe hypertriglyceridemia	Low price	Price competition

Vascepa gained a strategic advantage after the FDA approved its cardiovascular-risk-reduction indication based on the REDUCE-IT study. That indication materially expanded the value proposition of purified EPA beyond triglyceride lowering.[2]

Omtryg did not have an equivalent outcomes-based claim. Its commercial positioning remained tied to triglyceride reduction, where price competition was more severe.

What patents protected Omtryg?

Omtryg’s regulatory protection was more important than any durable product differentiation. The product was approved through the 505(b)(2) pathway, and the FDA Orange Book records the patent and exclusivity information associated with approved products.[3]

The principal legal risks for Omtryg were:

• Patent expiry affecting the active ingredient or formulation.
• ANDA filings by generic manufacturers.
• Paragraph IV challenges to listed patents.
• The limited scope of formulation claims for an oral omega-3 softgel.
• The ability of generic manufacturers to rely on the same active ingredient and therapeutic equivalence framework.

Omtryg’s active ingredients were not novel chemical entities. EPA and DHA ethyl esters had a long history of use in prescription and nonprescription products. Any defensible patent value therefore depended on formulation, dosage, manufacturing, or product-specific claims rather than ownership of the underlying molecules.

What formulation barriers existed?

The principal technical barriers were manufacturing consistency, oxidation control, fatty-acid composition, capsule stability, and bioequivalence. These barriers can delay or complicate generic development, but they do not necessarily support a long-term premium.

For an omega-3 softgel, relevant manufacturing controls include:

• Purity and concentration of EPA and DHA.
• Control of oxidation and peroxide formation.
• Uniformity across capsules.
• Stability during storage.
• Encapsulation and packaging technology.
• Analytical methods for fatty-acid composition.

These issues can affect product quality and regulatory review. They generally provide weaker commercial protection than a composition-of-matter patent or a clinically differentiated delivery system.

Were there Paragraph IV challenges or Omtryg patent settlements?

No major Omtryg Paragraph IV settlement or litigation outcome has become a defining feature of the U.S. omega-3 market. The principal market event was generic competition in the broader omega-3-acid ethyl ester category rather than a high-value patent dispute that preserved Omtryg’s commercial position.

The absence of a prominent settlement-driven delay is commercially relevant. In branded pharmaceuticals, a settlement can preserve revenue by postponing generic entry. Omtryg did not establish a comparable long-term delay mechanism in the public record.

FDA approval records, Orange Book data, and federal court dockets are the relevant sources for confirming listed patents, ANDA challenges, and litigation outcomes.[3,4]

What is the current FDA and Orange Book status of Omtryg?

Omtryg’s FDA history is tied to NDA 205977. The FDA label confirms its approved indication and active ingredients.[1] The Orange Book is the controlling public reference for listed patents and therapeutic-equivalence information.[3]

The commercial distinction is important:

• FDA approval establishes the legal basis to market the product.
• Orange Book listing can affect ANDA certification and patent litigation.
• Neither approval nor listing guarantees ongoing commercial distribution.
• A product may remain in FDA records while having little or no active branded sales.

Omtryg should therefore be analyzed as a product with historical approval and limited present commercial visibility, not as a major active branded asset.

Which companies challenged or competed with Omtryg?

Competition came primarily from product categories rather than from a single high-profile challenger.

Generic manufacturers

Generic pharmaceutical companies could compete through abbreviated new drug applications for omega-3-acid ethyl ester products. Their advantages included:

• Lower development cost than a new molecular entity.
• Established regulatory precedent.
• Automatic substitution potential after approval.
• Lower selling, general, and administrative costs.
• Payer preference for lower-cost products.

Large branded manufacturers

GlaxoSmithKline’s Lovaza established the category before Omtryg. Amarin’s Vascepa created a separate competitive segment based on purified EPA and cardiovascular-outcome data.

Nonprescription alternatives

Dietary supplements containing fish oil, EPA, DHA, or krill oil competed for patients outside strict prescription channels. These products were not interchangeable with Omtryg for regulatory purposes, but they affected patient and physician perceptions of omega-3 therapy and constrained willingness to pay.

What generic launch scenarios existed for Omtryg?

The likely generic-entry scenarios were straightforward:

Scenario	Market effect
Early generic approval after patent or exclusivity expiry	Rapid share loss and lower price
Multiple generic approvals	Severe price compression
Single authorized generic or limited competition	Slower erosion but reduced brand leverage
No active branded promotion	Accelerated prescription migration
Payer-mandated substitution	Minimal ability to preserve premium pricing

An Omtryg generic would not need to reproduce a novel biological mechanism. It would compete on equivalence, supply reliability, and price. That structure favored generic manufacturers and pharmacies rather than the branded sponsor.

How strong was the Omtryg patent estate?

The Omtryg patent estate was commercially weak relative to products protected by novel active ingredients, complex biologics, or clinically differentiated delivery systems.

Its potential strengths were:

• Product-specific formulation claims.
• Manufacturing controls related to oxidation and stability.
• Regulatory exclusivity associated with the 505(b)(2) approval.
• Possible process or composition claims covering the finished softgel.

Its structural weaknesses were:

• Publicly known EPA and DHA molecules.
• Established prior art in fish-oil and omega-3 formulations.
• Simple oral dosage form.
• Limited clinical differentiation from Lovaza.
• Generic substitution pressure.
• No outcome-based label supporting a separate premium market.

The estate could support a launch window, but it was unlikely to produce long-duration exclusivity comparable to a new chemical entity.

Did Omtryg generate licensing or acquisition value?

There is no broadly disclosed licensing transaction that assigned substantial standalone value to Omtryg. Trygg Pharma’s private-company structure limits visibility into licensing economics, milestone payments, manufacturing agreements, and product-level profitability.

The product’s strategic value was likely concentrated in:

• Entry into the U.S. prescription omega-3 market.
• Use of the 505(b)(2) pathway.
• Potential leverage with specialty pharmacies and distributors.
• Commercial validation of Trygg Pharma’s formulation and manufacturing capabilities.

Those factors did not translate into evidence of a large, durable revenue stream.

What is the outlook for Omtryg revenue?

The outlook is limited. Omtryg faces a mature therapeutic category, generic competition, weak brand differentiation, and no cardiovascular-outcome claim. Revenue would require an active commercial supply channel, formulary access, and protection from direct generic substitution.

The most defensible financial conclusion is:

• Historical revenue was likely modest relative to Lovaza and Vascepa.
• Peak sales were not publicly disclosed.
• Long-term revenue durability was low.
• Product-level profitability cannot be established from public filings.
• The commercial value of the asset is substantially lower than its initial FDA approval value.

Key Takeaways

• Omtryg is an EPA/DHA omega-3-acid ethyl ester product approved in 2014 for severe hypertriglyceridemia.
• Its FDA application was NDA 205977 and used the 505(b)(2) pathway.
• The product had limited differentiation from Lovaza and later generic omega-3 products.
• Vascepa gained a stronger strategic position through purified EPA and a cardiovascular-risk-reduction indication.
• Omtryg’s patent value depended on formulation, manufacturing, and regulatory protection rather than a novel active ingredient.
• Trygg Pharma did not publicly disclose standalone Omtryg revenue.
• The product did not become a major commercial franchise, and its long-term revenue trajectory was vulnerable to generic substitution.
• Current analysis should treat Omtryg as a low-visibility historical branded product rather than a major active U.S. growth asset.

FAQs

Is Omtryg the same as Lovaza?

Omtryg and Lovaza both contain omega-3-acid ethyl esters with EPA and DHA. They are related products, but they are separate branded products with separate regulatory histories and manufacturers.

Does Omtryg reduce the risk of heart attack or stroke?

The FDA label does not establish that Omtryg reduces cardiovascular mortality or morbidity. Its approved use is triglyceride reduction in adults with severe hypertriglyceridemia.[1]

Is Omtryg still commercially available in the United States?

FDA records establish the product’s approval history, but approval status does not confirm active commercial distribution. Public evidence does not support treating Omtryg as a major actively marketed U.S. brand.

Is there a generic version of Omtryg?

Generic omega-3-acid ethyl ester products compete in the same therapeutic category. Whether a particular product is therapeutically equivalent to Omtryg must be confirmed through the FDA Orange Book and current FDA approval records.[3]

Why did Vascepa outperform Omtryg commercially?

Vascepa used purified EPA and later received a cardiovascular-risk-reduction indication supported by REDUCE-IT. Omtryg remained focused on triglyceride lowering and lacked the same outcomes-based differentiation.[2]

References

1. U.S. Food and Drug Administration. (2014). Omtryg (omega-3-acid ethyl esters) prescribing information. Drugs@FDA.

2. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.